中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
8期
25-28,39
,共5页
子痫前期%血管内皮功能障碍%一氧化氮%一氧化氮供体%有机硝酸盐%S-亚硝基谷胱甘肽%L-精氨酸%西地那非
子癇前期%血管內皮功能障礙%一氧化氮%一氧化氮供體%有機硝痠鹽%S-亞硝基穀胱甘肽%L-精氨痠%西地那非
자간전기%혈관내피공능장애%일양화담%일양화담공체%유궤초산염%S-아초기곡광감태%L-정안산%서지나비
Preeclampsia%Endothelial dysfunction%Nitric oxide%Nitric oxide donors%Organic nitrates%S-nitrosoglutathione%L-arginine%Sildenafil
子痫前期是一种严重的具有不同临床表现的多系统疾病。目前研究发现,虽然没有明确的因果关系,内皮功能障碍以及一氧化氮生物利用度的降低可能会在发病的病理生理学中发挥重要作用。缺乏可以针对潜在的病理生理变化和逆转内皮功能障碍的治疗方法,往往会导致胎儿的医源性早产,引起新生儿发病率和死亡率的增高,以及产妇发病率和死亡率的增加。针对一氧化氮—可溶性鸟苷酸环化酶途径的各成分的药物可以有助于增加NO的生物利用度。此综述的目的是概述子痫前期在临床研究的治疗方法,重点是对一氧化氮供体包括有机硝酸盐和S-亚硝基硫醇,L-精氨酸,NO内源性前体;cGMP的分解抑制剂,包括西地那非,以及NO供体代谢新型抑制剂等。本研究概述了每种治疗模式的优点和局限性,并且对于子痫前期的既定治疗方案进行了探索。
子癇前期是一種嚴重的具有不同臨床錶現的多繫統疾病。目前研究髮現,雖然沒有明確的因果關繫,內皮功能障礙以及一氧化氮生物利用度的降低可能會在髮病的病理生理學中髮揮重要作用。缺乏可以針對潛在的病理生理變化和逆轉內皮功能障礙的治療方法,往往會導緻胎兒的醫源性早產,引起新生兒髮病率和死亡率的增高,以及產婦髮病率和死亡率的增加。針對一氧化氮—可溶性鳥苷痠環化酶途徑的各成分的藥物可以有助于增加NO的生物利用度。此綜述的目的是概述子癇前期在臨床研究的治療方法,重點是對一氧化氮供體包括有機硝痠鹽和S-亞硝基硫醇,L-精氨痠,NO內源性前體;cGMP的分解抑製劑,包括西地那非,以及NO供體代謝新型抑製劑等。本研究概述瞭每種治療模式的優點和跼限性,併且對于子癇前期的既定治療方案進行瞭探索。
자간전기시일충엄중적구유불동림상표현적다계통질병。목전연구발현,수연몰유명학적인과관계,내피공능장애이급일양화담생물이용도적강저가능회재발병적병리생이학중발휘중요작용。결핍가이침대잠재적병리생리변화화역전내피공능장애적치료방법,왕왕회도치태인적의원성조산,인기신생인발병솔화사망솔적증고,이급산부발병솔화사망솔적증가。침대일양화담—가용성조감산배화매도경적각성분적약물가이유조우증가NO적생물이용도。차종술적목적시개술자간전기재림상연구적치료방법,중점시대일양화담공체포괄유궤초산염화S-아초기류순,L-정안산,NO내원성전체;cGMP적분해억제제,포괄서지나비,이급NO공체대사신형억제제등。본연구개술료매충치료모식적우점화국한성,병차대우자간전기적기정치료방안진행료탐색。
Pre-eclampsia is a serious multisystem disorder with diverse clinical manifestations. Researches have shown that endothelial dysfunction and reduced nitric oxide bioavailability are likely to play an important role in the maternal and fetal pathophysiology. Lack of treatment modalities that can target the underlying pathophysiological changes and reverse the endothelial dysfunction frequently leads to iatrogenic preterm delivery of the fetus, causing neonatal morbidity and mortality, and maternal morbidity and mortality. Drugs that target various components of the nitric oxide: soluble guanylyl cyclase pathway can help to increase NO bioavailability. The purpose of this review is to outline the current status of clinical research involving these therapeutic modalities in the context of preeclampsia, with the focus being on nitric oxide donors including organic nitrates and S-nitrosothiols; L-arginine, the endogenous precursor of NO;inhibitors of cGMP breakdown including sildenafil, and other novel inhibitors of NO donor metabolism. The advantages and limitations of each modality are outlined and the development into established therapeutic options for preeclampsia is explored.